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Abstract
Background: The global health challenge of dementia is exceptional in size, cost and impact. It is the only top ten
cause of death that cannot be prevented, cured or substantially slowed, leaving disease management, caregiver
support and service innovation as the main targets for reduction of disease burden. Institutionalization of persons
with dementia is common in western countries, despite patients preferring to live longer at home, supported by
caregivers. Such complex health challenges warrant multicomponent interventions thoroughly implemented in
daily clinical practice. This article describes the rationale, development, feasibility testing and implementation
process of the LIVE@Home.Path trial.
Methods: The LIVE@Home.Path trial is a 2-year, multicenter, mixed-method, stepped-wedge randomized controlled
trial, aiming to include 315 dyads of home-dwelling people with dementia and their caregivers, recruited from 3
municipalities in Norway. The stepped-wedge randomization implies that all dyads receive the intervention, but the
timing is determined by randomization. The control group constitutes the dyads waiting for the intervention. The
multicomponent intervention was developed in collaboration with user-representatives, researchers and stakeholders
to meet the requirements from the national Dementia Plan 2020. During the 6-month intervention period, the
participants will be allocated to a municipal coordinator, the core feature of the intervention, responsible for regular
contact with the dyads to facilitate L: Learning, I: Innovation, V: Volunteering and E: Empowerment (LIVE). The primary
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outcome is resource utilization. This is measured by the Resource Utilization in Dementia (RUD) instrument and the
Relative Stress Scale (RSS), reflecting that resource utilization is more than the actual time required for caring but also
how burdensome the task is experienced by the caregiver.
Discussion: We expect the implementation of LIVE to lead to a pathway for dementia treatment and care which is
cost-effective, compared to treatment as usual, and will support high-quality independent living, at home.
Trial registration: ClinicalTrials.gov: NCT04043364. Registered on 15 March 2019.
Keywords: Home-dwelling, Dementia care, Service collaboration, Resource utilization, Caregiver burden, Stepped-
wedge randomization, Multicomponent interventions
Background
The world’s population is rapidly aging as a result of
fewer births and declining mortality rates [1]. The global
health challenge of dementia is exceptional in size, cost
and impact [2]. According to the World Health
Organization, the number of people living with dementia
is estimated to be 50 million worldwide, expected to al-
most triple by 2050 [3]. Despite most people, also from a
caregiver perspective, preferring to live longer at home,
and to die there, if possible [4, 5], about 30,000 of the es-
timated 80,000–100,000 persons with dementia (PWDs)
in Norway reside in nursing homes [6]. The urbanization
of our societies, in particular younger persons moving
toward central areas and leaving their older relatives be-
hind, underlines the need for cost-effective service col-
laboration to provide adequate treatment and care for
the aging home-dwelling population.
Rationale for the present trial
Among the top ten causes of death globally, dementia is
the only one that cannot be prevented, cured or substan-
tially slowed [7], leaving disease management, caregiver
support and service innovation as the top priority for
health policy-makers in the reduction of disease burden.
Due to expected positive interactions within the family,
interventions supporting them as caregivers not only po-
tentially lessen the caregivers’ burden [8], but could also
be beneficial for the PWD (e.g. reducing neuropsychi-
atric symptoms and delaying nursing home admission)
[9, 10]. As such, interventions supporting caregivers hold
the potential for better overall resource allocation and
utilization [11].
Caring for a PWD comes at a high cost, both individu-
ally and at societal level. Caregivers to PWDs have lower
perceived health and higher rates of mortality relative to
their noncaregiver counterparts [12]. The effect of prac-
tical assistance and psychoeducational programs have
been evaluated, but most single initiatives have fallen
short in reducing the caregivers’ burden [13]. The Maxi-
mizing Independence (MIND) at HOME study under-
taken in Baltimore, USA, during 2008–2010 included
approximately 300 home-dwelling persons with
cognitive impairment or dementia in a parallel random-
ized multicomponent trial [14, 15]. This study showed
that 18 months of care coordination through individual-
ized care planning, implementation of a care plan, moni-
toring and reassessment had beneficial effects on the
time to transition from home, number of dementia-
related unmet needs, quality of life (QoL) and, import-
antly, a potentially clinically relevant reduction in self-
reported number of hours spent on caregiving tasks, as a
measure of caregiver burden [14, 15]. Developing this
model further, the MIND at Home-Plus study included
an additional 340 persons to evaluate the effect on long-
term care placement, hospitalization and health-care ex-
penditures of a 24-month homecare coordination pro-
gram for PWD [16]. The MIND at Home-Streamlined
trial is now refining the intervention to investigate its
impact on time to long-term care placement, needs, bur-
dens and QoL in PWDs and their caregivers, as well as
cost utilization [17]. Results of the latter study are highly
anticipated due to the potential for effective system-level
approaches to dementia care [17]. Yet, due to fairly large
regional and cultural differences in care organization,
there is a need for implementation studies in other
countries to explore the generalizability of the program.
A multicomponent intervention is not merely a
discrete package of separate components, but a process
of changing what complex systems do [18]. Intervening
within a complex system involves disrupting prior ways
of working while introducing new ones [19]. The degree
of complexity can be understood as a relative construct,
defined by the number of components, diversity of the
intended outcome, number of targeted organizational
levels and level of skill required to deliver the interven-
tion [20], while additionally considering the interplay be-
tween context, setting and the implementation process
[21]. In the COSMOS trial, a randomized implementa-
tion hybrid trial carried out in Norwegian nursing homes
during 2014–2015, our group successfully developed,
implemented and effect evaluated a multicomponent
intervention addressing COmmunication, Systematic as-
sessment and treatment of pain, Medication review,
Organization of activities and Safety [22]. Overall, the
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intervention resulted in improved QoL and activities of
daily living (ADL), in addition to a decrease in neuro-
psychiatric symptoms such as agitation and depression
as well as a reduction in the number of medications used
among nursing home residents [23–27].
To provide cost-effective care while securing the needs
of PWDs and caregivers represents a complex health
challenge warranting multicomponent interventions im-
plemented in daily clinical practice. Aiming at system-
level change, such interventions require stakeholder in-
volvement as well as collaboration within and between
different levels of primary and specialist health-care ser-
vices, nongovernmental institutions, users and re-
searchers, addressing the need for appropriate and
coordinated cross-sector action.
Aim of the LIVE@Home.Path trial
The LIVE@Home.Path trial aims to develop, adapt, im-
plement and effect-evaluate a multicomponent interven-
tion for home-dwelling dyads of PWDs and their
caregivers, aiding them to stay safer, longer and more in-
dependently at home with cost-effectiveness. In this
study, caregivers are defined as family or close friends,
equaling informal caregivers. LIVE@Home.Path is an
acronym referring to each component of the complex
intervention: Learning, Innovation, Volunteer support
and Empowerment—At Home Pathway. The primary
outcome is resource utilization. This is measured by the
Resource Utilization in Dementia (RUD) instrument and
the Relative Stress Scale (RSS), reflecting that resource
utilization is more than the actual time required for
caregiving tasks, but also how burdensome the task is
experienced by the caregiver. Importantly, the caregiver
burden is individual, and may be related to economic
hardship, anxiety, depression, hopelessness, impaired
QoL or lack of sleep and time for recreation. This indi-
vidual perspective underlines the significance of user in-
volvement, reflected in the trial’s slogan: what matters to
you? Secondary outcomes include neuropsychiatric
symptoms, number of adverse events, use of assistive
technology, involvement of volunteers, QoL and clinical
global impression of change for the PWD as well as
caregivers’ depression, QoL and work performance.
Main hypothesis
The LIVE intervention will reduce time and resources
that caregivers spend in organizing and supporting
PWDs’ daily activities, thereby reducing the caregiver
burden.
Methods and design
The LIVE@Home.Path trial is a 2-year, multicenter,
mixed-method, stepped-wedge randomized controlled
trial (RCT). We aim to recruit 315 dyads of home-
dwelling PWDs and their caregivers from the municipal-
ities of Bergen, Bærum and Kristiansand.
Method of intervention development, implementation
and evaluation
Development of the LIVE intervention
Based on experiences with two pre-projects— Research
Council of Norway sponsor code 261626 (UiB) and
261605 (Haraldsplass Deaconess Hospital)— the inter-
vention was developed in collaboration with user-
representatives, stakeholders and scientific partners from
the Scientific Advisory Board. To meet the requirements
from the Dementia Plan 2020 by the Ministry of Health
and Care Services [28], we identified the “big issues” ex-
pected to facilitate support for home-dwelling PWDs
and their caregivers. As such, we combined and adapted
existing knowledge rather than designing new components,
contributing to service innovation in the health-care
systems. The process was tailored to meet the standards of
“Development–evaluation–implementation”, an inter-
nationally agreed approach for complex interventions
launched by the UK Medical Research Council [29].
The LIVE intervention
At the start of the 6-month intervention period, the
dyads will be allocated to a municipal coordinator, of-
fering regular contact to assist in finding a pathway
throughout the administrative trajectory of dementia
care. The coordinator should hold a bachelor degree
in health-related science (e.g. nursing, ergo or physio-
therapy), and will make a minimum of two home
visits, one immediately after the intervention start and
the second after approximately 3 months. Supplemen-
tary visits will be offered if needed, in addition to
monthly telephone calls. During the intervention, the
coordinator will introduce the dyads to the different
stages of the LIVE intervention: Learning, Innovation,
Volunteer support and Empowerment (Table 1, Fig. 1).
All components will be carefully adapted to local
conditions.
Learning A fruitful learning process is characterized by
relevance, timing, confidentiality and reflection as well as
fulfilment of expectations regarding content. The Demen-
tia Plan 2020 [28] underlines increased knowledge at all
societal levels as crucial for improvements in dementia
care. A meta-analysis on the effectiveness of educational
interventions supporting caregivers of community-
dwelling PWDs found a moderate impact on the caregiver
burden, a small effect on depression, but no effect on tran-
sition to long-term care [30]. A Norwegian multicenter
randomized controlled trial found no reduction in depres-
sive symptoms for PWDs and caregivers after a 12-month
psychosocial support program including formal education
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seminars [31]. Yet coping had a positive impact on the
caregiver burden in the latter study, possibly reflecting im-
proved understanding of the caregiver situation [31].
In practice in the LIVE@Home.Path: the coordinator
will encourage and facilitate that both the PWD and the
caregiver participate in local educational programs
arranged by the municipality or the specialist health ser-
vices several times yearly. As an example, the nationally
established educational program for relatives of PWDs is
developed by the Norwegian Advisory Unit on Ageing
and Health [32], and implemented for use in Bergen,
Bærum and Kristiansand.
Table 1 Components of the LIVE intervention in the LIVE@Home.Path trial
Learning Innovation Volunteer Empowerment
Content Local learning programs
covering key aspects of the
dementia syndrome, coping in
daily life, legal, safety and
economic issues
Tailored use of welfare technology
such as technical aids, cognitive
intervention devices and assisted
living systems/smart house systems
Service innovation
Data collection
PWDs often experience
social deprivation, and
volunteer support is a
politically highly prioritized
area in Norway
Support of relatives
End-of-life care and advance care
planning: a repeating process of
communication to investigate
values and wishes for domestic and
institutionalized treatment and care
(i.e. “What matters to you?”)
Systematic medication review by
the PWD’s general practitioner
Participants PWD
Caregivers
Coordinators
Volunteers
Teachers in the municipal and
specialized health-care services
PWD
Caregivers
Coordinators
PWD
Caregivers
Coordinators
Volunteers from nonprofit
organizations (The Red
Cross, Norwegian
Association for Public
Health)
Volunteer managers
PWD
Caregivers
Coordinators
General practitioner
Actions Coordinator:
• Inform about potential
lessons/courses for both
PWD and caregiver
• Search for practical
solutions to ensure
participation
Coordinator:
• Assess and evaluate usefulness
of devices already in use
• Inform about additional
available welfare technology in
the municipality
• Inform about specific
communication platforms
(Jodacare©, Friskus©), social
media forums (Facebook©) and
applications for tablets (Alight©)
Coordinator:
• Inform about volunteer
services
Volunteer manager:
• Match PWD with
volunteer after
assessment of
preferences and wishes
Coordinator:
• Initiate systematic medication
review with general practitioner
• Initiate advanced care planning
with general practitioner,
including issues on formal next of
kin, guardianship
• Facilitate application process for
home-based services
PWD person with dementia
Fig. 1 Learning (L), Innovation (I), Volunteering (V) and Empowerment (E)
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Innovation Innovation is understood as the application
of better and more original solutions to meet new require-
ments, unarticulated needs or existing market needs, or
employing established solutions in new areas, both
technological, such as information and communication
technology (ICT), and organizational. Crucially, the
process will result in more effective products, processes,
services, technologies or business models being made
available for all, including markets, government and soci-
ety [33]. As such, the LIVE@Home.Path can be viewed as
a service innovation, aiming at the development of a clin-
ical pathway for dementia care.
ICT approaches in elderly care are broadly categorized
as technical aids, cognitive intervention devices, and sen-
sor and assistive living systems [34]. ICT in dementia care
holds potential for optimizing safety at home, reducing
caregiver burden and, although the findings are not con-
clusive [35], possibly also improving cost-effectiveness.
Yet we have limited knowledge about which type of de-
vices are used, regarded as useful and requested by care-
givers and PWDs at different stages of dementia [36].
Most important, this field requires a careful, individual
risk–benefit assessment, as ICT might negatively impact
autonomy and privacy, and provide a false sense of safety.
In practice in the LIVE@Home.Path: the coordinator
will assess and evaluate the usefulness of ICT solutions
already in use for PWDs and caregivers and inform
about additional relevant welfare technology available in
the municipality. The participants will receive informa-
tion about a newly launched online communication plat-
form tailored to meet the needs of families organizing
dementia care (Jodacare©) [37], and be informed about a
web page with scheduled activities of relevance (Fris-
kus©) [38]. In Bergen, the participants will be invited to
test the prototype Alight©, an application for tablets
providing a “digital memory book” developed by Soun-
dio AS and NKS Olaviken Gerontopsychiatric Hospital
[39]. Additionally, up to ten participants in Bergen will
be invited to test a prototype of the adapted communi-
cation platform in collaboration with the Western
Norway University of Applied Sciences. Underlining the
aspects of service innovation, all data will be collected
on tablets owned by the project group via the software
SurveyJS [40]. The LIVE@Home.Path trial was selected
as a pilot for the development and evaluation of this
software, providing secure data transfer and storage on
the SAFE server at the University of Bergen for research
project with sensitive data. After approval from the prin-
cipal investigator, researchers affiliated with the project
will be given access to the server, avoiding export of data
and maintaining high levels of security [41].
Volunteer support Volunteer support is understood as
any activities that involves someone spending time,
unpaid and of one’s own will, doing something that aims
to benefit someone else outside their own families and
households [42]. Being important suppliers of unpaid
support, it is estimated that volunteers contributed 142,
000 full-time equivalents (FTEs) in Norway in 2017 [43].
However, the majority are engaged in sports and culture,
and representation in the elderly care sector is sparse
[44]. Volunteering among older adults reduces their de-
pressive symptoms, improves self-reported health and
functional performance, and increases survival [42, 45].
The volunteers additionally report better health through
their own engagement [46, 47]. Volunteerism has con-
tributed to the development of the Norwegian welfare
system through identifying and providing solutions to
societal challenges [48], being formally integrated into
core strategic plans in the health-care sector and being
launched as a prioritized political strategy in elderly and
dementia care in Norway [49]. Yet we have sparse know-
ledge about volunteer support schemes for home-
dwelling PWDs. To provide better services, understand-
ing of the dynamics, motivations and interactions in vol-
unteerism in dementia care is required.
In practice in the LIVE@Home.Path: the coordinator
will investigate PWD and caregiver attitudes toward vol-
unteer support, and inform about volunteer services. If
this is of interest, the coordinator will contact local
volunteer coordinators for nonprofit organizations (The
Red Cross [50] and The Norwegian Association for
Public Health [51]), aiming at the best possible match of
volunteers based on assessment of preferences and
wishes.
Empowerment Empowerment in dementia care can be
defined as “a confidence building process whereby PWD
are respected, have a voice and are heard, are involved
in making decisions about their lives and have the op-
portunity to create change through access to appropriate
resources” [52]. The process of advanced care planning
(ACP) can increase empowerment for PWDs and their
caregivers [26, 27], underlined by the Norwegian policy
guidance by the Directorate of Health on diagnosis,
treatment and care for PWDs [53]. PWDs do not neces-
sarily die from dementia, they die with it, and the life ex-
pectancy after onset of symptoms ranges from 4 to 11
years, depending on age and the presence of comorbidi-
ties [54]. The continuing process of communication
should be initiated as early as possible in collaboration
with the general practitioner as a comprehensive medical
examination including revision of medications, enabling
the PWD to clarify individual values and wishes for do-
mestic and institutionalized treatment and care (i.e.
“What matters to you?”).
In practice in the LIVE@Home.Path: the coordinator
will schedule a minimum of one appointment at the
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general practitioner’s office for empowering ACP, in-
cluding the issues of formal next of kin and guardian-
ship. In addition, a systematic medication review will be
undertaken to ensure use of medications in line with
diagnoses and symptoms, utilizing recommended guide-
lines [25].
The feasibility study
To evaluate the feasibility and the implementation strat-
egy of the coordinators of the LIVE intervention, a feasi-
bility study was conducted during 2018–2019. Sixteen
dyads in Bergen were assigned a coordinator for 6
months, participating in a minimum of two home visits
and providing monthly follow up by telephone. One
dyad dropped out after a few weeks of participation due
to permanent placement in a nursing home, leaving 15
dyads followed by 2 coordinators for assessment. Quali-
tative individual and focus group interviews utilizing a
hermeneutic approach were performed with six dyads,
three caregivers and the two coordinators as well as the
coordinators’ leader, exploring the usefulness of the co-
ordinator function. This process revealed that the core
feature of the coordinator was to support the caregivers
in finding, applying and organizing support, and to pro-
vide emotional care, support and guidance. The object-
ive of empowering the PWD in the decision-making
processes was nonetheless particularly difficult to
achieve. This finding was further incorporated into the
LIVE intervention for the stepped-wedge RCT, with in-
creased focus on the ACP process and follow up of the
GP [55].
Implementation process of the LIVE intervention
Implementation research is defined as the scientific in-
vestigation concerning the act of carrying an interven-
tion into effect in the real-world setting [56, 57]. Even a
superbly designed intervention will fail to change prac-
tice if the process of implementation is futile. In the
LIVE@Home.Path trial, the implementation can be
viewed as a two-stage process: first, from the research
team to the coordinators; and, second, from the coordi-
nators to the dyads. The first part encompasses all activ-
ities arranged by the research team empowering the
coordinators to standardize the implementation of the
intervention, such as seminars, development of written
material and follow-up of coordinators during the inter-
vention period. Six months prior to the intervention
start, kick-off workshops for all involved collaborators in
the municipalities, including coordinators and affiliated
specialized health services, will be arranged at all study
sites, facilitating enthusiasm, collaboration and recruit-
ment of participants. Two weeks before the intervention
start, a 2-day implementation seminar for the coordina-
tors will be delivered by the research team at all study
sites, training the coordinators through lectures, role-
play and discussions (see Additional file 1). Halfway
through the 6-month intervention period, a 1-day mid-
way evaluation workshop for the coordinators will be ar-
ranged, allowing for discussion of obstacles and pitfalls,
which acts as a source for facilitating a more effective
and standardized implementation. As a part of the inter-
vention, the research team will contact each coordinator
by telephone every 14 days to keep track of the process,
discuss potential challenges and follow-up use of the
Checklist for implementation of the intervention. This
ten-page pocket manual will contain a simplified how-
to-do description of the intervention components. It will
be filled out for each dyad by the coordinator, registering
time use and whether each of the distinct LIVE compo-
nents has been addressed during the intervention period.
Additionally, a 30-page tutorial will be developed as a
comprehensible introduction to the rationale, method
and practical aspects of the conduction of the trial,
aimed for an audience not skilled in the research
method.
The second part of the implementation process en-
compasses the coordinator–dyad relationship. The coor-
dinators are obliged to arrange a minimum of two home
visits during the intervention period, and provide
monthly contact by telephone. The Checklist for imple-
mentation of the intervention will be used at every con-
tact, and collected by the research team at the end of the
intervention, providing documentation for the imple-
mentation process.
Evaluation of the implementation process
In addition to the midway evaluation, a LIVE conference
will be organized for all coordinators at the end of the
third intervention period, collecting data on their experi-
ences of the suitability of the single components and the
implementation process. Additionally, at data collection
after the intervention period, the participants will be
asked if and to what extent they were offered the LIVE
components, and how often they were contacted by their
coordinator. As such, if the LIVE intervention fails to
prove an effect on resource utilization, it will be possible
to examine whether this is a result of the LIVE compo-
nents not being tailored to produce such an effect (i.e.
that our main hypothesis was wrong) or whether it was
caused by a lack of proper implementation. Evaluation
of the implementation process will further be investi-
gated by conducting qualitative interviews with the coor-
dinators as part of the mixed-method design.
Sample size calculations, settings and target populations
The required sample size was calculated to detect a dif-
ference of 7 h/week for the primary outcome RUD.
Based on the literature, we assumed that the mean
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number of hours of informal care is 46 h/week with a
standard deviation (SD) of 20 h/week [58]. With 80%
power and a significance level of 5%, the required sam-
ple size was estimated to be 260 dyads. To allow for 20%
loss to follow-up, a total of 315 dyads, equaling 105 per
municipality, must be included.
Participants will be recruited from memory clinics
at local hospitals, from municipal memory teams and
after advertisements in general media such as newspa-
pers, radio and TV in Bergen, Bærum and Kristian-
sand. Bergen is the second largest municipality of
Norway with approximately 280,000 inhabitants in
2018, Bærum is ranked the fifth largest with 127,000
inhabitants, while the 92,000 inhabitants of Kristian-
sand constitute Norway’s sixth largest municipality
[59].
PWDs are eligible for inclusion if they: are aged ≥ 65
years; are home-dwelling; have a minimum 1 h/week
regular face-to-face contact with the caregiver; are diag-
nosed with dementia according to standardized protocol
[60]; have Mini-Mental State Examination (MMSE)
score of 15–25; have a Functional Assessment Staging
Test (FAST) score of 4–7; and provide written informed
consent. Exclusion criteria are: participation in another
ongoing intervention trial; or expected survival < 4
weeks. PWDs are eligible for inclusion regardless of eti-
ology of the dementia and presence of other disorders.
Caregivers are eligible for inclusion if they have a mini-
mum of 1 h/week regular face-to-face contact with the
PMD and provide written informed consent. As such,
both the PWD and the caregiver will be included in the
trial, representing a dyad.
The mixed-method, stepped-wedge randomized control
design
Data from all 315 dyads will be assessed every 6 months
from baseline to the end of study period after 24months,
death or permanent residency in a nursing home—in total,
five waves of data collection. The stepped-wedge randomized
control design [61] implies that all participants will receive
the 6-month intervention program during the study period,
for which the timing of the intervention is determined by the
randomization (Fig. 2). The control group constitutes the
dyads waiting for the intervention at a given time during the
study; this group will have access to health care and receive
treatment as usual. Criteria for discontinuing the intervention
or participation are requested from participants to withdraw
from the trial. The trial’s user-oriented approach, aiming at
minimizing the participant burden associated with follow-up
visits, in addition to flexibility in scheduling of the visits are
sought to promote retention and prevent loss to follow-up
over the trial. No distinct adverse events are expected before
the start of the trial or during the trial, while possible adverse
events related to the change in prescribed medication during
the general practitioner’s medication review might occur. If
so, they will be reported by the coordinators to the re-
searchers, either immediately or at their regular follow-up
every 2 weeks (physical meeting, by phone or by e-mail), in
addition to feedback from the coordinator to the general
practitioner. A statistician will randomly allocate the order of
the intervention using block randomization; the dyads are
randomized in clusters within each geographical location.
The random sequence will be generated using a computer-
ized random number generator undertaken for all three mu-
nicipalities after the inclusion and baseline assessments are
completed for all participants. Research assistants, re-
searchers conducting the analyses and other study personal
conducting data collection will be blind to the randomization
order and to the implementation process of the intervention.
Participants will not be informed of the intervention and im-
plementation strategy to secure blinding until they are allo-
cated to their coordinator during the intervention period.
From this point of time, they become unblinded. Given the
practice change of the intervention, the municipality home-
care services will be aware when their cluster enters the
intervention period.
When developing a pathway for dementia care, incorp-
orating experiences and perspectives from the PWDs and
their caregivers is fundamental. In line with the INVOLVE
framework [62], this trial is developed through user in-
volvement from the conception of the idea, via design
through the implementation phase. At the structural level,
user involvement is secured via collaboration with the
head of research at the Norwegian Health Associations
[51], participating in the Steering committee, and locally
grounded by dementia coordinators in the municipalities.
At the individual level, the Centre for Elderly and Nursing
Home Studies (SEFAS), responsible for conducting the
trial, employs a user-representative as a co-researcher in a
10% position, who participates in the study’s advisory
board and working group. The mixed-method design [63]
encompasses the integration of data from quantitative as-
sessment of validated outcomes with material from quali-
tative interviews and participant observation. Utilizing an
exploratory hermeneutic design [64], in-depth and focus
group interviews with PWDs (n = 15), caregivers (n = 15),
municipality health-care staff (n = 20), general practi-
tioners (n = 10), volunteers (n = 18) and volunteer coordi-
nators (n = 6) will be conducted. To evaluate the
acceptability and feasibility of the communication plat-
form, interviews with caregivers and care staff will be
made, as well as real-life observations form use among
PWDs and caregivers.
Outcome measures
Table 2 presents the primary and secondary outcomes
according to domain, specific measurement, metric,
method of aggregation and time points. The primary
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outcome of the LIVE@Home.Path trial is formal and in-
formal resource utilization, measured by the RUD in-
strument [65, 66] and the RSS [67] (Table 2). As such,
we consider overall resource utilization as more than the
time required to care for the PWD; it also encompasses
how burdensome the task is experienced by the care-
giver. The informal care time use is measured in hours/
month [65, 68], in addition to numbers of contacts with
the health-care system and use of medications. The
RUD is a standardized and widely used instrument
assessing dementia care, proven useful across different
care systems and countries and in both clinical trials and
observational studies [65, 66]. Caregivers stress will be
assessed by the RSS, a self-report instrument covering
three dimensions of “emotional distress”, “social distress”
and “negative feelings”. It is regarded as a useful
instrument to stratify careers according to the risk of
psychiatric morbidity [69, 70].
The secondary outcomes presented in Table 2 include
measures of QoL, psychiatric symptom load, ADL, co-
morbidity and pain as well as measure of goal achieve-
ments. The QoL for both the PWD and the caregiver
will be measured by self-report using the Quality of Life
in Alzheimer’s disease scale (QoL-AD) [71] and the gen-
eric quality of life measure EQ-5D-5L [72], including the
EQ-5D-VAS scale [73]. Additionally, QoL for the PWD
will be assessed by proxy by the caregiver with the QoL-
AD [71]. Psychiatric symptoms for the PWD will be
proxy rated by the caregiver using the Neuropsychiatric
Inventory Questionnaire (NPI-12) [74], the Cohen-
Mansfield Agitation Inventory (CMAI) [75, 76] and the
Cornell Scale for Depression in Dementia (CSDD) [77],
Fig. 2 a Stepped-wedge randomized control design. The randomization in time takes place at month 0. First group (red) is in the intervention
period from month 1 to 6, second group (yellow) from month 7 to 12 and third group (green) from month 13 to 18. Implementation seminars
will be held at months 0, 6 and 12, and midway evaluation at months 3, 9 and 15. Data will be collected at baseline (month 0), after the first
intervention period (month 6–7), after the second intervention period (month 12–13), after the third intervention period (month 18–19) and at
the end of the study at 24 months. b Schedule of enrollment, interventions and assessments over the study period
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Table 2 Primary and secondary outcomes in the LIVE@Home.Path trial
Domain: name of
tool
Specific
measurement:
what the tool
measures
Characteristics of tool Metric Method of
aggregation
Time points
Primary outcome
Resource
Utilization in
Dementia (RUD)
(65, 66, 68)
Resource
utilization in
dementia care
Self-reported formal and informal
care time use in hours/30 days on
activities of daily living (e.g.
feeding, dressing, bathing) and
supervision (e.g. wandering,
preventing dangerous situations)
Assess number of contacts with
health-care professionals for both
PWD and caregivers in the last
30 days, and use of medications
High number of hours of direct
care time and numerous contacts
with health-care professionals in-
dicates high overall resource use
in dementia care
Change in hours/30
days
Mean Mean difference in hours/30 days
over the 6-month intervention
period summarized for the three
intervention groups compared to
mean difference in hours/30 days
summarized for the control
groupsa
Mean difference in hours/30 days
over the follow-up period in 6-
month intervals stratified by time
from end of interventionb
Relative Stress
Scale (RSS) (69,
70)
Caregiver distress 15 items for self-report of three
subgroups of distress: “emotional
distress”, “social distress” and
“negative feelings”
Each item ranging from 0 to 4
High score indicates high burden
and psychiatric morbidity
Change in total
score
Mean Mean difference in score over
the 6-month intervention period
summarized for the three inter-
vention groups compared to
mean difference in score summa-
rized for the control groupsa
Mean difference in score over
the follow-up period in 6-month
intervals stratified by time from
end of interventionb
Secondary outcomes
European Quality
of Life—5
Dimensions—5
Levels (EQ-5D-
5L) (72)
Generic quality
of life
Evaluates generic self-reported
health-related quality of life in re-
lation to resource use
Five items regarding mobility,
self-care, activities, pain/discom-
fort and anxiety/depression
scored on a five-level scale
Scores are converted to a single
summary index number
Change in total
score
Mean Mean difference in score over
the 6-month intervention period
summarized for the three inter-
vention groups compared to
mean difference in score summa-
rized for the control groupsa
Mean difference in score over
the follow-up period in 6-month
intervals stratified by time from
end of interventionb
EQ-5D-VAS scale
(73)
Quality of Life-
VAS scale
One-point measure of generic
self-reported health-related qual-
ity of life rated on a visual analog
scale from 0 to 100, high score
indicates good quality of life
Change in score Mean Mean difference in score over
the 6-month intervention period
summarized for the three inter-
vention groups compared to
mean difference in score summa-
rized for the control groupsa
Mean difference in score over
the follow-up period in 6-month
intervals stratified by time from
end of interventionb
Quality of Life in
Alzheimer’s
disease scale
(QoL-AD) (71)
Quality of life in
Alzheimer’s
dementia
Disease-specific self-reported
quality of life measure asses-
sing13 items each ranging from 1
to 4
High score indicates high quality
of life
Change in total
score
Mean Mean difference in score over
the 6-month intervention period
summarized for the three inter-
vention groups compared to
mean difference in score summa-
rized for the control groupsa
Mean difference in score over
the follow-up period in 6-month
intervals stratified by time from
end of interventionb
Neuropsychiatric
Inventory, 12-
item version
with caregiver
Neuropsychiatric
symptoms in
dementia
Proxy-rated presence, severity
and caregiver distress of 12 items
assessing depression, anxiety,
psychosis and motor
Change in total
score and change
in score for each
item
Mean, and
proportion
above clinical
significant
Mean difference in total and item
specific score over the 6-month
intervention period summarized
for the three intervention groups
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Table 2 Primary and secondary outcomes in the LIVE@Home.Path trial (Continued)
Domain: name of
tool
Specific
measurement:
what the tool
measures
Characteristics of tool Metric Method of
aggregation
Time points
distress (NPI-12)
(74)
disturbances
Range 0–144, high score
indicates frequent and severe
symptoms
The distress scale assess caregiver
distress associated with each
neuropsychiatric symptom, range
0–60, high score indicate
distressing symptoms
score compared to mean difference in
score summarized for the control
groupsa
Mean difference in total and item
specific score over the follow-up
period in 6-month intervals strati-
fied by time from end of
interventionb
Cohen-Mansfield
Agitation
Inventory (CMAI)
(75, 76)
Agitation in
dementia
29 items rated from 1 to 7 for
proxy assessment frequency of
agitated behavior
Range 29–203, high score
indicates frequent agitation
Change in total
score
Mean and
proportion
above clinical
significant
score
Mean difference in score over
the 6-month intervention period
summarized for the three inter-
vention groups compared to
mean difference in score summa-
rized for the control groupsa
Mean difference in score over
the follow-up period in 6-month
intervals stratified by time from
end of interventionb
Cornell Scale for
Depression in
Dementia
(CSDD) (77)
Depression in
dementia
19 items rated from 0 to 2 for
proxy assessment of depressive
symptoms in dementia
Range 0–38
Score≥ 8 indicates depression; ≥
12 indicates moderate–severe
depression
Change in total
score
Mean and
proportion
above clinical
significant
score
Mean difference in score over
the 6-month intervention period
summarized for the three inter-
vention groups compared to
mean difference in score summa-
rized for the control groupsa
Mean difference in score over
the follow-up period in 6-month
intervals stratified by time from
end of interventionb
Geriatric
Depression Scale
(GDS) (78)
Depression in
old age
30 items rated 0 or 1, for proxy
assessment of depressive
symptoms in the elderly
population
High score indicates high
symptom load
Change in total
score
Mean Mean difference in score over
the 6-month intervention period
summarized for the three inter-
vention groups compared to
mean difference in score summa-
rized for the control groupsa
Mean difference in score over
the follow-up period in 6-month
intervals stratified by time from
end of interventionb
Activities of Daily
Living,
Instrumental (I-
ADL) (76)
Functional level
for instrumental
activities
Eight items for proxy assessment
of use of telephone, shopping,
economy, public transport and
household
Range 8–31, high score indicates
poor functioning
Change in total
score
Mean Mean difference in score over
the 6-month intervention period
summarized for the three inter-
vention groups compared to
mean difference in score summa-
rized for the control groupsa
Mean difference in score over
the follow-up period in 6-month
intervals stratified by time from
end of interventionb
Activities of Daily
Living, Personal
(P-ADL) (79)
Functional level
for personal
activities
Six items rated 1–5 for proxy
assessment of personal activities
such as toileting, grooming,
dressing, transfer and eating
Range 6–30, high score indicates
poor functioning
Change in total
score
Mean Mean difference in score over
the 6-month intervention period
summarized for the three inter-
vention groups compared to
mean difference in score summa-
rized for the control groupsa
Mean difference in score over
the follow-up period in 6-month
intervals stratified by time from
end of interventionb
General Medical
Health Rating
Scale (GMRH)
Medical
comorbidity in
dementia
4-point Likert scale assessing
presence and severity of medical
conditions, scored by the
Ratings on the
Likert scale
transformed to
Mean Mean difference in score over
the 6-month intervention period
summarized for the three
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while caregiver psychiatric symptoms will be self-
reported using the Geriatric Depression Scale (GDS)
[78] in addition to the RSS [67]. Data on ADL for the
PWD will be proxy rated by the caregiver utilizing in-
strumental (I-ADL) and personal (P-ADL) measures
[79]. Data on pain will be obtained by self-report from
the PWD using the MOBID-2 Pain Scale [80–84] and
the level of comorbidity will be evaluated by the inter-
viewer according to the General Medical Health Rating
Scale (GMRH) [85]. The Clinical Global Impression of
Change Scale (CGIC) will be assessed after the interven-
tion to quantify and track patient progress and treat-
ment response [86]. In addition to the instruments
presented in Table 2, other outcome measures include
the number of adverse events (falls, disappearances out-
doors, fire hazard), use of assistive technology (number
of technical aids, cognitive intervention devices and
assisted living systems), involvement of volunteers (num-
ber of participants with contact with a volunteer, num-
ber of hours spent with a volunteer), number of
medications used (both regular and on demand) and
participation in educational programs for the PWD and
the caregiver. These outcome measures will be described
as the mean change in sum of events (number devices,
hours, medications, educational programs) over the
intervention period compared to controls (as outlined in
Table 2).
Quantitative data quality and collection
Prior to inclusion and baseline data collection, a 1-day
seminar will be arranged for the study personal to secure
training in the use of tablets and scoring of relevant psy-
chometric scales. A study manual has been developed to
guide data collectors during their visits to secure stan-
dardized reporting. Close to 24 h/day, telephone and
mail support will be offered by the research team during
times of data collection. Researchers and municipal
study personal will collect data at baseline as well as 6,
12, 18 and 24-month follow-up. The municipalities will
receive 5000 NOK per enrolled dyad to compensate for
extra administrative work. At baseline, demographic data
such as year of birth, gender, marital status, housing
characteristics, education and employment will be col-
lected, as well as data on the dementia syndrome, in-
cluding the current score on the Mini-Mental State
Examination, Norwegian Version (MMSE-NR3) [87, 88],
Table 2 Primary and secondary outcomes in the LIVE@Home.Path trial (Continued)
Domain: name of
tool
Specific
measurement:
what the tool
measures
Characteristics of tool Metric Method of
aggregation
Time points
(85) interviewer
High score indicates high
comorbidity burden
numeric scale to
estimate change in
total score
intervention groups compared to
mean difference in score summa-
rized for the control groupsa
Mean difference in score over
the follow-up period in 6-month
intervals stratified by time from
end of interventionb
Mobilization–
Observation–
Behavior–
Intensity
Dementia Pain
Scale (MOBID-2)
(80–84)
Pain in dementia 10 items rated 0–10 for proxy-
rated assessment of pain related
to the muscle–skeletal system
and pain that might be related to
internal organs, head and skin
High score indicates frequent and
severe pain
Change in overall
score and change
in score for each
item
Mean Mean difference in score over
the 6-month intervention period
summarized for the three inter-
vention groups compared to
mean difference in score summa-
rized for the control groupsa
Mean difference in score over
the follow-up period in 6-month
intervals stratified by time from
end of interventionb
Clinical Global
Impression of
Change (CGIC)
(86)
Clinical
meaningful
change
Quantifies and tracks patient
progress and treatment response
on a scale from 1 to 7, scored by
the interviewer
High score indicates worsening
Change in overall
score
Mean and
proportion
with
worsening, no
change and
improvement
Mean difference in score over
the 6-month intervention period
summarized for the three inter-
vention groups compared to
mean difference in score summa-
rized for the control groupsa
Mean difference in score over
the follow-up period in 6-month
intervals stratified by time from
end of interventionb
All assessment will be made by research personal or affiliated staff in the municipalities during home visits with the person with disability (PWD) and
the caregiver
aIntervention groups: group 1 (red), t1–t2; group 2 (yellow), t2–t3; group 3 (green), t3–t4. Control groups: (t1–t2 + t2–t3) (see Fig. 2a)
bGroup 1 (red): three 6-month periods, t2–t3, t3–t4 and t4–t5. Group 2 (yellow): two 6-month periods, t3–t4 and t4–t5. Group 3 (green): one 6-month period, t4–t5
(see Fig. 2a)
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Functional Assessment Staging Test (FAST) [89] and
The Informant Questionnaire on Cognitive Decline in
the Elderly (IQCODE) [90, 91]. The MMSE-NR3 [88]
will be assessed every 12 months during the trial.
Plan for quantitative data analyses
Intention-to-treat analyses will be performed accounting
for municipality as a random effect in mixed-effect models
and the generalized estimating equation (GEE) with non-
linear effect comparing the intervention groups to con-
trols. Repeated observations within persons will be
accounted for with a correlation matrix. All secondary
outcomes will be adjusted for multiple comparisons using
the Hochberg method [92]. Given the potentially inform-
ative censoring due to dropout, institutionalization and
death, we will jointly model the primary outcome and at-
trition through a shared person-specific random intercept.
Missing data will be handled using multiple imputations
by chained equations (MICE).
Ethical approval
The study was approved in May 2019 by the Regional
Committee for Medical and Health Research Ethics,
North Norway (2019/385) and West Norway (2017/
1519) (the pilot), and registered at ClinicalTrials.gov
(NCT04043364). Assessment and utilization of personal
data from the dyads as well as from volunteers and vol-
unteer coordinators from nonprofit organizations are ap-
proved by the Norwegian Centre for Research Data
(NSD) (ref. 514093). After verbal and written informa-
tion, spoken and written informed consent was obtained
in direct conversation with the caregiver and the PWD,
if capable of providing consent for participation. If not,
the next of kin or a legal advocate provided consent
based on their determination on whether the PWD,
when they were able, would have agreed to participate in
the trial.
Discussion
Compared to care as usual, we expect the LIVE@Home.-
Path trial to innovate the clinical pathway in dementia
care, facilitating cost-effective, feasible and independent
living at home through Learning, Innovation, Volunteer-
ing and Empowerment.
Framework for sustainable ethic innovation in dementia
research
Participation in research is based on affirmative, unam-
biguous, informed and specific consent [93]. Persons
with cognitive impairment will often not be able to pro-
vide such a comprehensive consent or understand the
scope and consequences of data assessment. Local legis-
lation for obtaining ethical permission in studies varies
substantially between European countries [94]. In
Norway, the next of kin or a legal advocate can provide
consent based on their determination of whether the
person, when they were able, would have agreed to par-
ticipate in the trial [23]. These principles for obtaining
informed consent were applied in the LIVE@Home.Path
trial. From 2018, the European Union-wide law on data
protection, the General Data Protection Regulation
(GDPR), represents a significant step toward protection
of participants in research [95]. In particular, Article 6
protects PWDs and their relatives from being coerced to
consent without awareness of how their data will be
used [96, 97]. When assessing sensitive data such as
mental health, Article 35 requires a Data Protection Im-
pact Assessment (DPIA), a formal process systematically
analyzing, identifying and minimizing the data protec-
tion risks of a project. We developed a DPIA (ePhorte
UiB: 2019/5569) for the LIVE@Home.Path trial in col-
laboration with the Data Protection Official at the
University of Bergen, encouraging us to again evaluate
which data to assess, as well as focus on safe data man-
agement. Nonetheless, we anticipate the participation in
the LIVE@Home.Path trial to be less burdensome rela-
tive to, for example, RCTs on effect of medications, due
to the user-oriented approach emphasizing the investiga-
tion of the perspective “What matters to you?”
Stakeholders and research funders increasingly require
patient and public involvement (PPI) at all stages of re-
search from design, implementation and dissemination
of results, shifting focus from research “about” or “for”
to research “with” or “by” someone [98, 99]. Our user-
representative has provided feedback on a close to
weekly basis through participation in the working group
and advisory board of the trial. A related principle, Re-
sponsible Research and Innovation (RRI), is defined as a
transparent, interactive process making societal actors
and innovators mutually responsive to each other, and
encouraging them to set up a critical perspective when
evaluating the innovation and marketability of products
[100, 101]. Taken together, these components constitute
a framework for sustainable ethic innovation in demen-
tia research (Fig. 3), a model that easily can be applied
when designing and conducting research on other vul-
nerable patient groups.
Methodological considerations
A stepped-wedge randomized controlled trial design is
recommended for evaluation of a multicomponent inter-
vention in health-care services as it provides a number
of practical and scientific benefits compared to an ordin-
ary RCT [61]. It is increasingly used in effectiveness
studies in the geriatric field [102, 103]. Most import-
antly, the design allows for providing the intervention to
all participants, overcoming ethical and logistical chal-
lenges arising from withholding the intervention. This
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design is, however, more vulnerable to temporal external
changes, as more participants are exposed to the inter-
vention toward the end of the study than in earlier
stages. If the LIVE intervention fails to prove an effect
on resource utilization, we will examine whether this is
due to a lack of proper implementation. Thus, if the im-
plementation process is satisfactory, it may suggest that
the LIVE components were not tailored to be sufficiently
cost-effective if no effects on primary outcome measures
are found. An alternative interpretation is that the inter-
vention may not be cost-effective even if primary out-
comes change significantly, as resource use by the
intervention is more time consuming and/or expensive
than the alternative.
Practical pitfalls and obstacles
Some challenges have emerged during the start of the
trial. First, it is demanding to include the estimated num-
ber of participants, and, additionally, to keep the number
of dropouts low due to the progression of the disease. We
should have established closer collaborations with the
geriatric specialist health-care services, as we experienced
that patients recruited from geriatric outpatient clinics
were in the most optimal disease stage for this trial. To in-
crease recruitment, we prolonged the inclusion period to
31 December 2019 and expanded the inclusion criteria to
age ≥ 64 years and MMSE range 15–27, while the SEFAS
researchers, journalist and co-researcher with user experi-
ence continuously work on positive media coverage. Sec-
ond, data collection from home-dwelling persons in three
distinct municipalities is resource and logistically
demanding. Third, being selected as a pilot for the data
collection software has been challenging, as the file format
initially generated handled missing data in a way that was
not compatible with our statistical programs. Finally, the
participants have so far been recruited in various ways,
from home-care services in the municipality and memory
clinics at hospitals, to self-referrals after advertisements in
the general media. This implies that the dyads included in
our trial represent a heterogeneic group of home-dwelling
people with dementia.
In conclusion, we expect the implementation of LIVE
to lead to a pathway for dementia treatment and care
that is cost-effective, feasible and supports independent
living, at home.
Trial status
A total of 428 dyads had been screened for participation
from 20 May 2019, of which 279 were included in the
trial. By January 2020, when recruitment ended, 31
dyads had dropped out. Mainly due to a more rapid in-
clusion process than anticipated, this protocol was sub-
mitted after the end of the recruitment period but in
due time before the last visit for data collection. At the
time of resubmission in May 2020, the COVID-19 pan-
demic had profoundly impacted the Norwegian health-
care system, including services in the municipal sector,
challenging the implementation of the intervention in
group 2. Newsletters with status, possible modifications
and upcoming events will be sent by e-mail to the site
leaders and coordinators every 2–3 months. Final proto-
col version number 5 will be prepared by 1 June 2019.
Fig. 3 Framework for sustainable ethic innovation in dementia research
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